Exelixis

Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
Fri, 06/1/18 - 09:37 am
Exelixis
Cabometyx
Tecentriq
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
Mon, 05/28/18 - 02:14 pm
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Thu, 05/17/18 - 09:42 am
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
CP Wire
Thu, 05/10/18 - 09:57 am
Roche
Exelixis
Tecentriq
Cotellic
colorectal cancer
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Thu, 05/10/18 - 09:52 am
Roche
Exelixis
Tecentriq
Cotellic
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
CP Wire
Thu, 05/3/18 - 11:09 am
Exelixis
Invenra
cancer
Merck
drug development
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
Wed, 05/2/18 - 08:46 pm
Exelixis
Invenra
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Endpoints
Wed, 04/11/18 - 11:02 am
Roche
Tecentriq
clinical trials
colon cancer
Exelixis
Cotellic
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Thu, 01/4/18 - 10:04 pm
Exelixis
Cabometyx
renal cell carcinoma
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Reuters
Wed, 12/20/17 - 09:39 am
Pfizer
Exelixis
Cabometyx
kidney cancer
Bosulif
blood cancer
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Motley Fool
Thu, 10/5/17 - 06:14 pm
Exelixis
Bristol-Myers Squibb
Opdivo
3 Monster Biotech Stocks in the Making
Motley Fool
Sun, 09/24/17 - 10:24 am
biotech
Exelixis
Incyte
Vertex Pharmaceuticals
Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
Investors Business Daily
Sat, 09/16/17 - 12:11 pm
Amgen
Eli Lilly
JNJ
Exelixis
biotech
Theravance
Bavarian Nordic
Agios
Biohaven Pharmaceuticals
Progenics
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Thu, 09/14/17 - 06:56 pm
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Motley Fool
Sat, 09/9/17 - 09:28 am
Exelixis
earnings
Cabometyx
Exelixis and Genentech hammer out new deal terms
BioPharma Dive
Fri, 07/21/17 - 10:10 am
Exelixis
Genentech
Cotellic
melanoma
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Wed, 07/12/17 - 10:05 am
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
Motley Fool
Wed, 07/5/17 - 07:08 pm
biotech
M&A
Exelixis
Portola Pharmaceuticals
Intercept Pharmaceuticals
Exelixis clears debt, turning eye to future growth
BioPharma Dive
Thu, 06/29/17 - 02:24 pm
debt
Exelixis
Exelixis, Inc. Turns a Profit, but Don't Get Too Excited
Motley Fool
Wed, 03/1/17 - 08:51 pm
Exelixis
earnings

Pages